The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway

1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis

(2021) Rui-yuan Pan et al.   ACTA PHARMACOLOGICA SINICA

Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells

(2021) Ane Olazagoitia-Garmendia et al.   GUT

Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation

(2021) Hongxu Xian et al.   IMMUNITY

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

(2021) Teresa WM Fan et al.   eLife

Melatonin Attenuates Neuroinflammation by Down-Regulating NLRP3 Inflammasome via a SIRT1-Dependent Pathway in MPTP-Induced Models of Parkinson’s Disease

(2021) Ran Zheng et al.   Journal of Inflammation Research

Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice

(2020) Jinbo Cheng et al.   Autophagy

Baicalin prevents LPS-induced activation of TLR4/NF-κB p65 pathway and inflammation in mice via inhibiting the expression of CD14

(2020) Ya-jun Fu et al.   ACTA PHARMACOLOGICA SINICA

NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients

(2020) Sunny Malhotra et al.   BRAIN

Synthetic vitamin K analogs inhibit inflammation by targeting the NLRP3 inflammasome

(2020) Xicui Zheng et al.   Cellular & Molecular Immunology

Prostaglandin F 2α receptor antagonist attenuates LPS‐induced systemic inflammatory response in mice

(2020) Toko Maehara et al.   FASEB JOURNAL

Blood–Brain Barrier Leakage Is Increased in Parkinson’s Disease

(2020) Sarah Al-Bachari et al.   Frontiers in Physiology

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis

(2019) Yanan An et al.   FASEB JOURNAL

“The SINE compound KPT-350 blocks dystrophic pathologies in DMD zebrafish and mice”

(2019) Rylie M. Hightower et al.   MOLECULAR THERAPY

Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease

(2019) Md. Ezazul Haque et al.   MOVEMENT DISORDERS

PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression

(2019) Yaw-Dong Lang et al.   Nature Communications

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

(2018) Yi Huang et al.   EMBO Molecular Medicine

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

(2018) Hongbin He et al.   Nature Communications

REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis

(2018) Shuai Wang et al.   Nature Communications

The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease

(2018) Shuo Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

(2017) Hua Jiang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus

(2016) Naoki Tajiri et al.   CNS Neuroscience & Therapeutics

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells

(2016) Cheryl Taylor-Kashton et al.   JOURNAL OF CELLULAR PHYSIOLOGY

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

(2016) J Etchin et al.   LEUKEMIA

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

(2016) Trinayan Kashyap et al.   Oncotarget

c-Abl–p38α signaling plays an important role in MPTP-induced neuronal death

(2015) R Wu et al.   CELL DEATH AND DIFFERENTIATION

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

(2015) Eric I. Elliott et al.   IMMUNOLOGICAL REVIEWS

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

(2015) Rebecca C Coll et al.   NATURE MEDICINE

Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination

(2015) Jeffery D Haines et al.   NATURE NEUROSCIENCE

NLRP3 inflammasome and its inhibitors: a review

(2015) Bo-Zong Shao et al.   Frontiers in Pharmacology

Targeting nucleocytoplasmic transport in cancer therapy

(2015) Richard Hill et al.   Oncotarget

Mechanism of NLRP3 inflammasome activation

(2014) Fayyaz S. Sutterwala et al.   Annals of the New York Academy of Sciences

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Targeting the Nuclear Transport Machinery by Rational Drug Design

(2013) Lei Mao et al.   CURRENT PHARMACEUTICAL DESIGN

Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes

(2012) Hye-Mi Lee et al.   DIABETES

Sequence and structural analyses of nuclear export signals in the NESdb database

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice

(2012) Michael T. Heneka et al.   NATURE

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

Recognition of nuclear targeting signals by Karyopherin-β proteins

(2010) Darui Xu et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE